|
- XOLAIR® (omalizumab) | Allergic Asthma, CSU, CRSwNP Food Allergy . . .
Learn about XOLAIR®, a self-administered treatment for allergic asthma, chronic rhinosinusitis with nasal polyps, chronic spontaneous urticaria, and food allergy See full prescribing, safety, Boxed Warning info
- Allergic Asthma | XOLAIR® (omalizumab)
Access information on allergic asthma and learn how XOLAIR may help treat the symptoms of allergic asthma See full prescribing, safety, Boxed Warning info
- Dosing and Administration | XOLAIR® (omalizumab)
XOLAIR ® (omalizumab) for subcutaneous use is an injectable prescription medicine used to treat moderate to severe persistent asthma in people 6 years of age and older whose asthma symptoms are not well controlled with asthma medicines called inhaled corticosteroids
- Starting XOLAIR® (omalizumab)
XOLAIR ® (omalizumab) for subcutaneous use is an injectable prescription medicine used to treat moderate to severe persistent asthma in people 6 years of age and older whose asthma symptoms are not well controlled with asthma medicines called inhaled corticosteroids
- Food Allergy Treatment | XOLAIR® (omalizumab)
Learn about XOLAIR® (omalizumab), the only FDA-approved treatment to reduce allergic reactions following accidental exposure to one or more foods See full prescribing and safety info, including Boxed Warning
- Allergic Asthma Treatment | XOLAIR® (omalizumab)
XOLAIR ® (omalizumab) for subcutaneous use is an injectable prescription medicine used to treat moderate to severe persistent asthma in people 6 years of age and older whose asthma symptoms are not well controlled with asthma medicines called inhaled corticosteroids
- Using Xolair® (omalizumab) For Chronic Hives Treatment
Learn about XOLAIR® (omalizumab) as a treatment option for chronic hives, also known as chronic spontaneous urticaria (CSU) See full prescribing, safety, Boxed Warning info
- XOLAIR® (omalizumab) Pricing | Cost
Learn about the the cost of XOLAIR® (omalizumab) injections See full prescribing, safety, Boxed Warning info
|
|
|